다제내성 시대의 임균 치료

키워드

참고문헌 (53)

1. Marrazzo JM, "Mandell, Douglas and Bennett’s Principles and Practice of Infectious Diseases" (2010), Elsevier
2. Fleming DT, "From epidemiological synergy to public health policy and practice: the contribution of other sexually transmitted diseases to sexual transmission of HIV infection", Sex Transm Infect, 75, pp.3~17 (1999)
3. World Health Organization, "Global incidence and prevalence of selectable curable sexually transmitted infections: 2008" (2012), WHO
4. Unemo M, "Antibiotic resistance in Neisseria gonorrhoeae: origin, evolution, and lessons learned for the future", Ann N Y Acad Sci, 1230, pp.E19~E28 (2011)
5. Yokoi S, "Threat to cefixime treatment for gonorrhea", Emerg Infect Dis, 13, pp.1275~1277 (2007)
6. Lo JY, "Ceftibuten resistance and treatment failure of Neisseria gonorrhoeae infection", Antimicrob Agents Chemother, 52, pp.3564~3567 (2008)
7. Unemo M, "High-level cefixime- and ceftriaxone-resistant Neisseria gonorrhoeae in France: novel penA mosaic allele in a successful international clone causes treatment failure", Antimicrob Agents Chemother, 56, pp.1273~1280 (2012)
8. Allen VG, "Neisseria gonorrhoeae treatment failure and susceptibility to cefixime in Toronto", JAMA, 309, pp.163~170 (2013)
9. Lewis DA, "Global resistance of Neisseria gonorrhoeae: when theory becomes reality", Curr Opin Infect Dis, 27, pp.62~67 (2014)
10. Lewis DA, "The Gonococcus fights back: is this time a knock out", Sex Transm Infect, 86, pp.415~421 (2010)
11. Deguchi T, "Treatment of uncomplicated gonococcal urethritis by doubledosing of 200 mg cefixime at a 6-h interval", J Infect Chemother, 9, pp.35~39 (2003)
12. Ito M, "Remarkable increase in central Japan in 2001-2002 of Neisseria gonorrhoeae isolates with decreased susceptibility to penicillin, tetracycline, oral cephalosporins, and fluoroquinolones", Antimicrob Agents Chemother, 48, pp.3185~3187 (2004)
13. Barry PM, "The use of cephalosporins for gonorrhea: the impending problem of resistance", Expert Opin Pharmacother, 10, pp.555~577 (2009)
14. Bolan GA, "The emerging threat of untreatable gonococcal infection", N Engl J Med, 366, pp.485~487 (2012)
15. Centers for Disease Control and Prevention (CDC), "Cephalosporin susceptibility among Neisseria gonorrhoeae isolates-- United States, 2000-2010", MMWR Morb Mortal Wkly Rep, 60, pp.873~877 (2011)
16. Chisholm SA, "GRASP Collaborative Group. Emergence of a Neisseria gonorrhoeae clone showing decreased susceptibility to cefixime in England and Wales", J Antimicrob Chemother, 66, pp.2509~2512 (2011)
17. Cole MJ, "The European gonococcal antimicrobial surveillance programme, 2009", Euro Surveill, 16 (2011)
18. Golparian D, "Emergence, spread and characteristics of Neisseria gonorrhoeae isolates with in vitro decreased susceptibility and resistance to extended-spectrum cephalosporins in Sweden", Sex Transm Infect, 86, pp.454~460 (2010)
19. Kirkcaldy RD, "Gonococcal resistance: are cephalosporins next", Curr Infect Dis Rep, 13, pp.196~204 (2011)
20. Kubanova A, "The Russian gonococcal antimicrobial susceptibility programme (RU-GASP)--national resistance prevalence in 2007 and 2008, and trends during 2005-2008", Euro Surveill, 15 (2010)
21. European Centre for Disease Prevention and Control, "Gonococcal antimicrobial susceptibility surveillance in Europe–2010" (2012), European Centre for Disease Prevention and Control
22. Cámara J, "Molecular characterization of two high-level ceftriaxoneresistant Neisseria gonorrhoeae isolates detected in Catalonia, Spain", J Antimicrob Chemother, 67, pp.1858~1860 (2012)
23. Tapsall JW, "Meeting the public health challenge of multidrug- and extensively drug-resistant Neisseria gonorrhoeae", Expert Rev Anti Infect Ther, 7, pp.821~834 (2009)
24. Pandori M, "Mosaic penicillin-binding protein 2 in Neisseria gonorrhoeae isolates collected in 2008 in San Francisco, California", Antimicrob Agents Chemother, 53, pp.4032~4034 (2009)
25. Unemo M, "Treatment failure of pharyngeal gonorrhoea with internationally recommended first-line ceftriaxone verified in Slovenia, September 2011", Euro Surveill, 17 (2012)
26. Ohnishi M, "Is Neisseria gonorrhoeae initiating a future era of untreatable gonorrhea?: detailed characterization of the first strain with high-level resistance to ceftriaxone", Antimicrob Agents Chemother, 55, pp.3538~3545 (2011)
27. Shimuta K, "Antibiotic-Resistant Gonorrhea Study Group. Antimicrobial resistance and molecular typing of Neisseria gonorrhoeae isolates in Kyoto and Osaka, Japan, 2010 to 2012: intensified surveillance after identification of the first strain (H041) with high-level ceftriaxone resistance", Antimicrob Agents Chemother, 57, pp.5225~5232 (2013)
28. Centers for Disease Control and Prevention (CDC), "Update to CDC's Sexually transmitted diseases treatment guidelines, 2010: oral cephalosporins no longer a recommended treatment for gonococcal infections", MMWR Morb Mortal Wkly Rep, 61, pp.590~594 (2012)
29. Workowski KA, "Sexually transmitted diseases treatment guidelines, 2010", MMWR Recomm Rep, 59, pp.1~110 (2010), Centers for Disease Control and Prevention (CDC)
30. Choi SM, "Update to Sexually Transmitted Infection Korean Treatment Guidelines", Korea Centers for Disease Control and Prevention, ~ (2013)
31. Ison CA, "GRASP collaborative group. Decreased susceptibility to cephalosporins among gonococci: data from the Gonococcal Resistance to Antimicrobials Surveillance Programme (GRASP) in England and Wales, 2007-2011", Lancet Infect Dis, 13, pp.762~768 (2013)
32. Tapsall JW, "Implications of current recommendations for third-generation cephalosporin use in the WHO Western Pacific Region following the emergence of multiresistant gonococci", Sex Transm Infect, 85, pp.256~258 (2009)
33. Bignell C, "2009 European (IUSTI", WHO) guideline on the diagnosis and treatment of gonorrhoea in adults, 2009, pp.20, 453~457
34. Unemo M, "Recommended antimicrobial treatment of uncomplicated gonorrhoea in 2009 in 11 East European countries: implementation of a Neisseria gonorrhoeae antimicrobial susceptibility programme in this region is crucial", SexTransm Infect, 86, pp.442~444 (2010)
35. Takahashi S, "Antimicrobial susceptibility and penicillinbinding protein 1 and 2 mutations in Neisseria gonorrhoeae isolated from male urethritis in Sapporo, Japan", J Infect Chemother, 19, pp.50~56 (2013)
36. Muratani T, "Single dose 1 g ceftriaxone for urogenital and pharyngeal infection caused by Neisseria gonorrhoeae", Int J Urol, 15, pp.837~842 (2008)
37. Newman LM, "Update on the management of gonorrhea in adults in the United States", Clin Infect Dis, 44(Suppl 3), pp.S84~S101 (2007)
38. Bignell C, "UK national guideline for the management of gonorrhoea in adults, 2011", Int J STD AIDS, 22, pp.541~547 (2011)
39. Furuya R, "In vitro synergistic effects of double combinations of beta-lactams and azithromycin against clinical isolates of Neisseria gonorrhoeae", J Infect Chemother, 12, pp.172~176 (2006)
40. Chisholm SA, "High-level azithromycin resistance occurs in Neisseria gonorrhoeae as a result of a single point mutation in the 23S rRNA genes", Antimicrob Agents Chemother, 54, pp.3812~3816 (2010)
41. Starnino S, "Azithromycin-resistant Neisseria gonorrhoeae strains recently isolated in Italy", J Antimicrob Chemother, 63, pp.1200~1204 (2009)
42. Katz AR, "Neisseria gonorrhoeae with high-level resistance to azithromycin: case report of the first isolate identified in the United States", Clin Infect Dis, 54, pp.841~843 (2012)
43. Barbee LA, "Control of Neisseria gonorrhoeae in the era of evolving antimicrobial resistance", Infect Dis Clin North Am, 27, pp.723~737 (2013)
44. Boslego JW, "Effect of spectinomycin use on the prevalence of spectinomycin-resistant and of penicillinase-producing Neisseria gonorrhoeae", N Engl J Med, 317, pp.272~278 (1987)
45. Unemo M, "Neisseria gonorrhoeae strain with high-level resistance to spectinomycin due to a novel resistance mechanism (mutated ribosomal protein S5) verified in Norway", Antimicrob Agents Chemother, 57, pp.1057~1061 (2013)
46. Chisholm SA, "An evaluation of gentamicin susceptibility of Neisseria gonorrhoeae isolates in Europe", J Antimicrob Chemother, 66, pp.592~595 (2011)
47. Dowell D, "Effectiveness of gentamicin for gonorrhoea treatment: systematic review and meta-analysis", Postgrad Med J, 89, pp.142~147 (2013)
48. Ross JD, "Cephalosporin resistant Neisseria gonorrhoeae: time to consider gentamicin", Sex Transm Infect, 88, pp.6~8 (2012)
49. Bignell C, "Azithromycin in the treatment of infection with Neisseria gonorrhoeae", Sex Transm Infect, 86, pp.422~426 (2010)
50. Unemo M, "In vitro activity of ertapenem versus ceftriaxone against Neisseria gonorrhoeae isolates with highly diverse ceftriaxone MIC values and effects of ceftriaxone resistance determinants: ertapenem for treatment of gonorrhea", Antimicrob Agents Chemother, 56, pp.3603~3609 (2012)
51. Unemo M, "Emergence of multidrug-resistant, extensively drug-resistant and untreatable gonorrhea", Future Microbiol, 7, pp.1401~1422 (2012)
52. Golparian D, "In vitro activity of the new fluoroketolide solithromycin (CEM-101) against a large collection of clinical Neisseria gonorrhoeae isolates and international reference strains, including those with high-level antimicrobial resistance: potential treatment option for gonorrhea", Antimicrob Agents Chemother, 56, pp.2739~2742 (2012)
53. Llano-Sotelo B, "Binding and action of CEM-101, a new fluoroketolide antibiotic that inhibits protein synthesis", Antimicrob Agents Chemother, 4, pp.4961~4970 (2010)

관련 논문AI추천